Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: (S)-crizotinib induces apoptosis in human non-small cell lung cancer cells by activating ROS independent of MTH1

Fig. 1

(S)-crizotinib induces NSCLC cell apoptosis independently of its effect on MTH1. a The effects of (S)-crizotinib on the viability of human NSCLC cells. NCI-H460, H1975, and A549 cells were challenged with increasing doses of (S)-crizotinib (0.625–80 μM) for 24 h. Cell viability was determined by MTT assay and the IC50 values (24 h) were calculated. b NCI-H460 cells transfected with siRNA against MTH1 and whole cell lysates were used to assess MTH1 protein levels. GAPDH was used as internal control. c Effect of MTH1 knockdown on the viability of NCI-H460 cells. d Induction of apoptosis in NSCLC cells was determined by annexin V/PI staining of cells following treatment with (S)-crizotinib (10, 20 or 30 μM) for 24 h. e Quantification of annexin V/PI staining showing the percentage of apoptotic cells following (S)-crizotinib treatment [*P < 0.05 compared to DMSO control]. NCI-H460 f and H1975 g cells were treated with (S)-crizotinib for 24 h. Cell lysates were then subjected to assessment of apoptosis-related proteins by western blot. GAPDH was used as internal control. Data representative of 5 independent experiments

Back to article page